What records are connected here?
- Evidence lanes
- 3
- Source years
- 2
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsNot a peptideMetabolic and weight
Also called Foundayo1
Not a peptide: a small molecule often looked up alongside peptides.
Orforglipron is a small-molecule drug, not a peptide, that binds to and activates the human GLP-1 receptor, according to its label.1,3 FDA approved it as Foundayo on April 1, 2026, to reduce excess body weight and keep it off in adults with obesity, or with overweight and a weight-related condition, alongside diet and physical activity.1,2 In the 72-week ATTAIN-1 trial of 3,127 adults with obesity, people taking it lost 7.5% to 11.2% of their body weight on average, compared with 2.1% on placebo. The label carries a boxed warning about thyroid C-cell tumors.1,3
| Substance type | Not a peptide. The 2025 ATTAIN-1 trial report describes orforglipron as a small-molecule, nonpeptide GLP-1 receptor agonist.3 |
|---|---|
| What it is | A synthetic small-molecule, nonpeptide agonist of the GLP-1 receptor, the active ingredient of Foundayo.1,3 |
| FDA status | FDA-approved. Drugs@FDA lists Foundayo with an original approval date of April 1, 2026. The label has a boxed warning about the risk of thyroid C-cell tumors.1,2 |
| Human evidence | Two 72-week randomized, double-blind, placebo-controlled trials, in 3,127 adults with obesity or overweight and in 1,613 adults with overweight and type 2 diabetes, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Orforglipron is a synthetic compound that activates the GLP-1 receptor. The ATTAIN-1 report describes it as a small-molecule, nonpeptide GLP-1 receptor agonist.3
In the United States it is the active ingredient of Foundayo, approved under NDA 220934, according to Drugs@FDA. The label gives its chemical formula, as a calcium salt, as C48H47F2N10O5 with half a calcium atom.1,2
The label states that it binds to and activates the human GLP-1 receptor. GLP-1 is a natural regulator of appetite, and its receptors are found in brain regions that control appetite and food intake.1
According to the label it reduces food intake, probably by lowering appetite, slows stomach emptying and causes more loss of fat than of lean mass.1
ATTAIN-1 randomly assigned 3,127 adults with obesity and without diabetes to one of three strengths of orforglipron or placebo for 72 weeks, alongside diet and exercise advice. Average weight change was −7.5%, −8.4% and −11.2% with orforglipron, compared with −2.1% with placebo.3
In the highest-strength group, 54.6% of people lost at least 10% of their weight, compared with 12.9% on placebo. Side effects leading to stopping treatment occurred in 5.3% to 10.3% of people on orforglipron and 2.7% on placebo; the most common were gastrointestinal and mostly mild to moderate.3
The label also describes a second 72-week trial in 1,613 adults with overweight or obesity and type 2 diabetes.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Foundayo, NDA 220934, with an original approval date of April 1, 2026.2
The Foundayo label cited here (DailyMed SPL version 10, published August 13, 2026) states that it is indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition.1
The label carries a boxed warning about the risk of thyroid C-cell tumors, which have been seen in rodents with GLP-1 receptor drugs. It states that orforglipron is not active in rats or mice and did not produce tumors in rodents, and that the relevance to humans has not been determined. It must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.1
The label also states that it is not recommended together with another GLP-1 receptor agonist.1
Whether it lowers the risk of heart attack, stroke or death: the label describes trials whose main measure was weight change after 72 weeks.1
How weight changes after the 72 weeks the trials lasted, and whether the thyroid finding in rodent studies of other GLP-1 drugs is relevant to people, which the label states has not been determined.1,3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Orforglipron: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Orforglipron are a bounded selection, not every registration or paper about Orforglipron. For the years before Orforglipron was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Orforglipron as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Orforglipron in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Foundayo for weight reduction in adults. Approval rests on two 72-week randomized trials, in 3,127 adults with obesity and 1,613 adults with type 2 diabetes. The label carries a boxed warning about thyroid C-cell tumors.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Foundayo for weight reduction in adults. Approval rests on two 72-week randomized trials, in 3,127 adults with obesity and 1,613 adults with type 2 diabetes. The label carries a boxed warning about thyroid C-cell tumors.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Drugs@FDA application NDA220934↗Source date April 1, 2026Literature metadata · added November 16, 2026
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.↗Source date November 9, 2026Literature metadata · added November 16, 2026
Orforglipron for Obstructive Sleep Apnea: Research Summary.↗Source date November 9, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
25 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.
7 of 7 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.
PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.
7 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span July 1, 2025 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
The New England Journal of Medicine · Official source · Source checked November 16, 2026